An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application.

During the interview, there are references made to various materials which can be found/downloaded/seen via the links on the right.

The audio interview with Dr. Carter can be heard below:

Disclosure: No Positions

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites